Chemistry:Adavosertib
From HandWiki
| |
| Names | |
|---|---|
| Preferred IUPAC name
1-[6-(2-Hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-(prop-2-en-1-yl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one | |
| Other names
AZD1775; MK-1775
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| KEGG | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C27H32N8O2 | |
| Molar mass | 500.607 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Tracking categories (test):
Adavosertib (development codes AZD1775, MK-1775) is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity.[1] It is being developed by AstraZeneca.[2] It is being investigated as a treatment for pancreatic cancer with a phase 1 trial (University of Michigan researchers are as of 2019 planning a phase 2 study.[3]), and ovarian cancer, in combination with another anti-cancer drug, gemcitabine, as a phase 2 trial.[4][5][6]
References
- ↑ "NCI Drug Dictionary" (in en). 2 February 2011. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/wee1-inhibitor-azd1775.
- ↑ "AZD1775 | AstraZeneca Open Innovation" (in en). https://openinnovation.astrazeneca.com/azd1775.html.
- ↑ "AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival" (in en). https://www.fiercebiotech.com/research/astrazeneca-drug-heads-to-phase-2-pancreatic-cancer-after-small-trial-extends-survival.
- ↑ Lheureux, Stephanie; Cristea, Mihaela C.; Bruce, Jeffrey P.; Garg, Swati; Cabanero, Michael; Mantia-Smaldone, Gina; Olawaiye, Alexander B.; Ellard, Susan L. et al. (2021-01-23). "Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial". Lancet 397 (10271): 281–292. doi:10.1016/S0140-6736(20)32554-X. ISSN 1474-547X. PMID 33485453.
- ↑ "Early Activity in Pancreatic Cancer With New Drug" (in en). 16 August 2019. https://www.medpagetoday.com/hematologyoncology/othercancers/81661.
- ↑ "Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer". Journal of Clinical Oncology 37 (29): 2643–2650. October 2019. doi:10.1200/JCO.19.00730. PMID 31398082.
 |  |
